Maltotetraose

Maltotetraose can serve as a substrate for enzyme-linked assays to measure amylase activity in biological fluids. Maltotetraose has oral active, and reduces TNF-α-induced inflammatory responses by inhibiting NF-κB activity and decreasing ICAM-1 expression. Maltotetraose also inhibits PDGF-induced vascular smooth muscle cell migration and neovascularization. Additionally, Maltotetraose derivatives can function as probes for detecting bacterial infections by targeting the maltodextrin transporter. With good long-term safety, Maltotetraose holds promise for research in atherosclerosis-related diseases^[1][2][3][4]. In Vitro:Maltotetraose (20-40 μM, 30 min) suppresses NF-κB activation and ICAM-1 expression, potentially aiding in the early prevention of atherosclerosis^[2].
Maltotetraose (20 μM, 30 min) inhibits PDGF-induced vascular smooth muscle cell migration, suggesting a potential role in atherosclerosis prevention^[2].
In Vivo:Maltotetraose (10% in diet or 5,000 mg/kg via p.o., once daily for 90 days) dose not induce significant toxicity, suggesting good long-term safety^[1].